Literature DB >> 7766533

Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology.

N Müller1, M Ackenheil.   

Abstract

Alterations of the cerebrospinal fluid (CSF) protein contents and the blood brain barrier (BBB) in schizophrenia have been observed by several authors but no relationship to clinical characteristics like psychopathology, the course or the duration of the disease could be described until now. We have studied 27 schizophrenic patients upon each of whom a lumbar punction had been carried out for clinical reasons. The average values of the patients were within the normal range. Nine patients (33%) showed the total protein content to be > 45 mg% and 6 (22%) > 50 mg%. In the latter 6 patients an impaired BBB (raised albumin CSF/serum quotient) and in 4 patients (15%) a raised CSF immunoglobulin (IgG) were observed. No relation to the patient's age and the duration of the disease was found but correlations with the Scale for the Assessment of Negative Symptoms (SANS) showed significant results in the subscores "affective flattening/affective blunting", "alogia/paralogia" as well as in the total score with respect to the CSF contents of albumin and IgG (p = 0.009-0.02). These correlations suggest that the CSF albumin and the CSF IgG are related to the negative symptomatology in schizophrenia and that patients with these CSF alterations may have a higher risk of developing negative symptoms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7766533     DOI: 10.1016/0920-9964(94)00045-a

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  Antibodies directed to Neisseria gonorrhoeae impair nerve growth factor-dependent neurite outgrowth in Rat PC12 cells.

Authors:  B Reuss
Journal:  J Mol Neurosci       Date:  2013-11-08       Impact factor: 3.444

3.  Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis.

Authors:  Juan A Gallego; Emily A Blanco; Sehba Husain-Krautter; E Madeline Fagen; Paula Moreno-Merino; Juan A Del Ojo-Jiménez; Anthony Ahmed; Thomas L Rothstein; Todd Lencz; Anil K Malhotra
Journal:  Schizophr Res       Date:  2018-07-17       Impact factor: 4.939

Review 4.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

5.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

6.  Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases.

Authors:  J Brettschneider; A Claus; J Kassubek; H Tumani
Journal:  J Neurol       Date:  2005-04-01       Impact factor: 4.849

Review 7.  Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications.

Authors:  Barbara Sperner-Unterweger
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Antibodies directed to the gram-negative bacterium Neisseria gonorrhoeae cross-react with the 60 kDa heat shock protein and lead to impaired neurite outgrowth in NTera2/D1 cells.

Authors:  B Reuss; A R Asif
Journal:  J Mol Neurosci       Date:  2014-02-28       Impact factor: 3.444

Review 9.  Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations.

Authors:  Norbert Müller
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

10.  Breaching the blood-brain barrier as a gate to psychiatric disorder.

Authors:  Hadar Shalev; Yonatan Serlin; Alon Friedman
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.